Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.
Center for Quantitative Health, Center for Genomic Medicine and Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.
Mol Cancer Res. 2021 May;19(5):757-770. doi: 10.1158/1541-7786.MCR-20-0188. Epub 2021 Jan 25.
Gliomas are characterized by diffuse infiltration of tumor cells into surrounding brain tissue, and this highly invasive nature contributes to disease recurrence and poor patient outcomes. The molecular mechanisms underlying glioma cell invasion remain incompletely understood, limiting development of new targeted therapies. Here, we have identified phosphotyrosine adaptor protein ShcD as upregulated in malignant glioma and shown that it associates with receptor tyrosine kinase Tie2 to facilitate invasion. In human glioma cells, we find that expression of ShcD and Tie2 increases invasion, and this significant synergistic effect is disrupted with a ShcD mutant that cannot bind Tie2 or hyperphosphorylate the receptor. Expression of ShcD and/or Tie2 further increases invadopodia formation and matrix degradation in U87 glioma cells. In a coculture model, we show that U87-derived tumor spheroids expressing both ShcD and Tie2 display enhanced infiltration into cerebral organoids. Mechanistically, we identify changes in focal adhesion kinase phosphorylation in the presence of ShcD and/or Tie2 in U87 cells upon Tie2 activation. Finally, we identify a strong correlation between transcript levels of ShcD and Tie2 signaling components as well as N-cadherin in advanced gliomas and those with classical or mesenchymal subtypes, and we show that elevated expression of ShcD correlates with a significant reduction in patient survival in higher grade gliomas with mesenchymal signature. Altogether, our data highlight a novel Tie2-ShcD signaling axis in glioma cell invasion, which may be of clinical significance. IMPLICATIONS: ShcD cooperates with Tie2 to promote glioma cell invasion and its elevated expression correlates with poor patient outcome in advanced gliomas.
神经胶质瘤的特征是肿瘤细胞弥漫性浸润周围脑组织,这种高度侵袭性的特性导致疾病复发和患者预后不良。神经胶质瘤细胞侵袭的分子机制尚不完全清楚,限制了新的靶向治疗方法的发展。在这里,我们已经确定磷酸酪氨酸衔接蛋白 ShcD 在恶性神经胶质瘤中上调,并表明它与受体酪氨酸激酶 Tie2 结合,促进侵袭。在人类神经胶质瘤细胞中,我们发现 ShcD 和 Tie2 的表达增加了侵袭性,而 ShcD 突变体不能与 Tie2 结合或过度磷酸化受体,则破坏了这种显著的协同作用。ShcD 和/或 Tie2 的表达进一步增加了 U87 神经胶质瘤细胞中的侵袭小体形成和基质降解。在共培养模型中,我们表明表达 ShcD 和 Tie2 的 U87 衍生肿瘤球体显示出增强的渗透到脑类器官中。在机制上,我们在 U87 细胞中发现了 Tie2 激活时 ShcD 和/或 Tie2 存在时粘着斑激酶磷酸化的变化。最后,我们发现 ShcD 和 Tie2 信号成分以及 N-钙粘蛋白在高级神经胶质瘤中的转录水平之间存在很强的相关性,以及在具有经典或间充质亚型的神经胶质瘤中,并且我们表明 ShcD 的高表达与具有间充质特征的高级别神经胶质瘤患者的生存显著降低相关。总之,我们的数据强调了神经胶质瘤细胞侵袭中 Tie2-ShcD 信号轴的新作用,这可能具有临床意义。
ShcD 与 Tie2 合作促进神经胶质瘤细胞侵袭,其高表达与高级神经胶质瘤患者的不良预后相关。